Emergent BioSolutions CFO: 4,995 shares withheld for taxes
Emergent BioSolutions (EBS) disclosed an insider administrative transaction by its EVP and Chief Financial Officer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Emergent BioSolutions (EBS) disclosed an insider administrative transaction by its EVP and Chief Financial Officer. On 10/15/2025, 4,995 common shares were withheld (Transaction Code F) at $9.6 to cover taxes upon vesting and settlement of restricted stock units. After this transaction, the officer directly beneficially owns 291,497 shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise Price or Tax Liability | Common Stock | 4,995 | $9.60 | $48K |
Footnotes (1)
- F1. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did EBS report in this Form 4?
What does Transaction Code F mean in this context?
Who is the reporting person and their relationship to EBS?
Was this trade under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.